- $1.20bn
- $1.25bn
- $606.88m
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
US RESEARCH ROUNDUP-Bank7, Goldman Sachs, Morgan Stanley
Deals of the day-Mergers and acquisitions
US STOCKS ON THE MOVE-Caterpillar, Kimberly-Clark, Bending Spoons
US STOCKS ON THE MOVE-Walmart, Super Micro, FMC
Deals of the day-Mergers and acquisitions
OPKO jumps on sale of select assets to Labcorp for up to $872 mln
Labcorp to buy select assets from Opko Health unit for up to $872 million
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Opko Health Inc Reports Results For The Quarter Ended June 30: Earnings Summary
OPKO Health Q2 loss narrows on higher IP revenue, lower costs
Opko Health Inc Expected To Post A Loss Of 8 Cents A Share: Earnings Preview
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
OPKO Health Q1 revenue falls after asset sales
Brief: OPKO Health Q1 Net Income USD -54.8 Million